These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 27021197)

  • 1. An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens.
    Younossi ZM; Stepanova M; Henry L; Nader F; Hunt S
    Am J Gastroenterol; 2016 Jun; 111(6):808-16. PubMed ID: 27021197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens.
    Younossi ZM; Stepanova M; Henry L; Nader F; Younossi Y; Hunt S
    Medicine (Baltimore); 2016 Jul; 95(28):e4151. PubMed ID: 27428205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens.
    Younossi ZM; Stepanova M; Nader F; Henry L
    J Am Geriatr Soc; 2016 Feb; 64(2):386-93. PubMed ID: 26825683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir.
    Younossi ZM; Stepanova M; Chan HLY; Lee MH; Yu ML; Dan YY; Choi MS; Henry L
    Medicine (Baltimore); 2016 Mar; 95(9):e2702. PubMed ID: 26945356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens.
    Stepanova M; Thompson A; Doyle J; Younossi I; de Avila L; Younossi ZM
    J Infect Dis; 2018 Mar; 217(7):1033-1043. PubMed ID: 29293991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity.
    Younossi ZM; Stepanova M; Esteban R; Jacobson I; Zeuzem S; Sulkowski M; Henry L; Nader F; Cable R; Afendy M; Hunt S
    Medicine (Baltimore); 2017 Feb; 96(7):e5914. PubMed ID: 28207507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study.
    Younossi ZM; Stepanova M; Zeuzem S; Dusheiko G; Esteban R; Hezode C; Reesink HW; Weiland O; Nader F; Hunt SL
    J Hepatol; 2014 Aug; 61(2):228-34. PubMed ID: 24713186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.
    Younossi ZM; Stepanova M; Nader F; Jacobson IM; Gane E; Nelson D; Lawitz E; Hunt SL
    Hepatology; 2014 Jun; 59(6):2161-9. PubMed ID: 24710669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
    Younossi ZM; Stepanova M; Sulkowski M; Foster GR; Reau N; Mangia A; Patel K; Bräu N; Roberts SK; Afdhal N; Nader F; Henry L; Hunt S
    Clin Infect Dis; 2016 Oct; 63(8):1042-1048. PubMed ID: 27444413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir.
    Younossi ZM; Stepanova M; Omata M; Mizokami M; Walters M; Hunt S
    Medicine (Baltimore); 2016 Aug; 95(33):e4243. PubMed ID: 27537553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
    Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
    Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection.
    Younossi ZM; Stepanova M; Henry L; Han KH; Ahn SH; Lim YS; Chuang WL; Kao JH; Nguyen KV; Lai CL; Chan HL; Wei L
    J Viral Hepat; 2018 Dec; 25(12):1429-1437. PubMed ID: 29974665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials.
    Younossi Z; Stepanova M; Omata M; Mizokami M; Walters M; Hunt S
    Health Qual Life Outcomes; 2017 Jan; 15(1):25. PubMed ID: 28143559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life.
    Younossi ZM; Stepanova M; Nader F; Lam B; Hunt S
    Aliment Pharmacol Ther; 2015 Aug; 42(3):286-95. PubMed ID: 26059536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.
    Younossi ZM; Stepanova M; Marcellin P; Afdhal N; Kowdley KV; Zeuzem S; Hunt SL
    Hepatology; 2015 Jun; 61(6):1798-808. PubMed ID: 25627448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus.
    Younossi ZM; Stepanova M; Sulkowski M; Naggie S; Henry L; Hunt S
    J Viral Hepat; 2016 Nov; 23(11):857-865. PubMed ID: 27291391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.
    Younossi ZM; Stepanova M; Pol S; Bronowicki JP; Carrieri MP; Bourlière M
    Liver Int; 2016 Jan; 36(1):42-8. PubMed ID: 26059860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
    Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.
    Younossi ZM; Stepanova M; Feld J; Zeuzem S; Sulkowski M; Foster GR; Mangia A; Charlton M; O'Leary JG; Curry MP; Nader F; Henry L; Hunt S
    Clin Gastroenterol Hepatol; 2017 Mar; 15(3):421-430.e6. PubMed ID: 27847279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
    Tao T; Jiang X; Chen Y; Song Y
    Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.